Investors appear to be buying on the dip after yesterday’s sell-off.

Key Points

Moderna stock fell on Monday after the publication of a scientific paper opposing booster doses.

Shares appear to be rebounding today as investors realize any short-term decisions on boosters aren’t likely to impact Moderna very much.

What happened

Shares of Moderna (NASDAQ:MRNA) were bouncing back by 3.6% as of 11:04 a.m. EDT on Tuesday after falling 6% on Monday. The rebound appears to be due to investors buying on the dip after digesting news that some top scientists are opposing booster doses for messenger RNA vaccines.

So what

There’s a pretty good case to be made that yesterday’s sell-off of vaccine stocks was overdone. For one thing, it remains to be seen what impact that opposition to boosters will have on upcoming U.S. government decisions.

Image source: Getty Images.

More importantly, though, the U.S. has already bought enough COVID-19 vaccine doses to provide boosters for all Americans. Even if boosters aren’t given a green light, it won’t have much financial impact (if any) on Moderna over the near term.

In addition, the group of scientists that contributed to a paper published in The Lancet on Monday acknowledged that boosters might be required if the efficacy of current vaccines declines. Moderna could still benefit if boosters are indeed needed over the longer term.

Now what

The Food and Drug Administration is convening an advisory panel on Friday to discuss booster doses. Moderna’s share price could experience another swing, either up or down, based on what the panel recommends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Motley Fool Returns

Stock Advisor

S&P 500



Join Stock Advisor

Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.

Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return



Moderna, Inc.






Why Moderna Stock Is Bouncing Back Today @themotleyfool #stocks $MRNA

Next Article

Read More